Business EconomyPosted at: Jun 12 2025 2:33PM


Bharat Biotech partners with GSK to develop a next-generation Shigella vaccine candidate

Hyderabad, June 12 (UNI) Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and manufacturing, announced on Thursday that it has partnered with GSK plc, a global biopharma company, for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3.
Shigellosis is an acute human inflammatory disease of the large intestine caused by Gram-negative Shigella. Watery diarrhea, fever, abdominal cramps and pain, and bloody and mucus-filled stools characterize it.
The agreement marks a critical step in the advancement of this promising vaccine, targeting Shigellosis—a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries, Hyderabad-based BBL said in a release here.
This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access.
The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials.
A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response, while subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns.
Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals.
The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally.
With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results.
It has already demonstrated a strong safety and immunogenicity profile in both European and African trials, including in the primary target population of 9-month-old infants.
Now entering Phase 3 trials under Bharat Biotech’s leadership, altSonflex1-2-3 is poised to become the first scalable, affordable, and globally accessible vaccine to combat this urgent public health threat.
GMMA technology is an innovative platform that uses bacterial outer membranes to deliver the O Antigen to the immune system.
This novel approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations.
BBL Executive Chairman Dr. Krishna Ella , said, "As the market leader in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi, Bharat Biotech is proud to partner with GSK to develop a next-generation Shigella vaccine candidate, for a severe form of bacterial diarrhoea affecting millions of children under five. With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment. The use of GMMA technology reflects our mission to deliver accessible vaccines that protect and improve lives worldwide."
As part of this agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the Access and Delivery Plans and commercialization strategy. GSK has an established relationship with BBIL, after signing a product transfer agreement for the world’s first malaria vaccine, RTS,S, to the Indian Biotech company in 2021, Dr Ella added.
Thomas Breuer, Chief Global Health Officer, GSK, said, “With young children in lower-income countries disproportionately impacted by Shigella, the development of a low-cost vaccine is an important goal for global public health. We are proud to collaborate with Bharat Biotech, whose expertise in developing and supplying vaccines for infectious diseases, especially as a trusted supplier to Gavi, the Vaccine Alliance, and UNICEF, positions them to further advance this important work. This agreement allows us to combine our strengths in science, research, and technology with Bharat Biotech's capacity to develop and deliver vaccines at scale, potentially preventing illness and saving lives around the world."
UNI KNR BD
Tags: #Bharat Biotech partners with GSK to develop a next-generation Shigella vaccine candidate
More News
Sensex crashes by 895 43 points

Sensex crashes by 895 43 points

13 Jun 2025 | 10:19 AM

Mumbai, June 13 (UNI) The BSE Sensex on Friday crashed by 895.43 points to 80,796.55 in early trade, as Israel’s military strikes on Iranian nuclear facilities sent shockwaves through global markets, triggering a risk-off mood across asset classes and amplifying domestic concerns following the fatal crash of an Air India Dreamliner.

see more..

Anupam Rasayan India Ltd signs MPA with a Japanese Multinational Conglomerate

12 Jun 2025 | 9:03 PM

Mumbai, Jun 12 (UNI)Anupam Rasayan India Ltd on Thursday said that it has signed a long-term Master Purchase Agreement (MPA) with a Japan-based Multinational Conglomerate., a global leader in fluorochemicals and advanced technology solutions.

see more..

Torrent Green Energy wins 300 MW wind project

12 Jun 2025 | 8:21 PM

New Delhi, June 12 (UNI) Torrent Green Energy Private Limited, a wholly owned subsidiary of Torrent Power Limited, has bagged a 300 MW wind power project under the Wind Tranche-XVIII auction conducted by the Solar Energy Corporation of India (SECI).

see more..

Flipkart and Telangana govt host workshop on ‘e-Commerce for Meeseva representative'

12 Jun 2025 | 6:21 PM

Hyderabad, June 12 (UNI) Flipkart, India’s homegrown e-commerce marketplace, in collaboration with the Government of Telangana, conducted a workshop here on Thursday aimed at equipping MeeSeva representatives with the knowledge and skills required to facilitate market access for local businesses through e-commerce.

see more..

Hyd: Cyient partners with MIPS to develop ASIC and ASSP solutions

12 Jun 2025 | 5:26 PM

Hyderabad, June 12 (UNI) Cyient Semiconductors Private Limited, a fast-growing custom silicon company based in Hyderabad, and MIPS, a global leader in RISC-V processor IP, on Thursday announced a strategic collaboration to develop domain-optimized ASIC (application-specific integrated circuit) and ASSP (application-specific standard product) solutions that leverage the MIPS Atlas portfolio of advanced, efficient processor IP.

see more..